• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Viral Vector Vaccines Are Victorious Against COVID-19 in Patients with Cirrhosis.

作者信息

Ferreira Raphaella D, John Binu V

机构信息

Division of Gastroenterology and Hepatology, Miami VA Medical Center, 1201 NW 16th Street, Miami, FL, 33125, USA.

Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

Dig Dis Sci. 2023 Feb;68(2):349-351. doi: 10.1007/s10620-022-07644-z. Epub 2022 Aug 10.

DOI:10.1007/s10620-022-07644-z
PMID:35947303
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9363849/
Abstract
摘要

相似文献

1
Viral Vector Vaccines Are Victorious Against COVID-19 in Patients with Cirrhosis.病毒载体疫苗在肝硬化患者中对新冠病毒取得成功。
Dig Dis Sci. 2023 Feb;68(2):349-351. doi: 10.1007/s10620-022-07644-z. Epub 2022 Aug 10.
2
[Advances in clinical research of virus vector-based COVID-19 vaccines].
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Aug 6;56(8):1127-1135. doi: 10.3760/cma.j.cn112150-20211101-01008.
3
Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.失代偿期肝硬化患者和肝移植受者对冠状病毒病疫苗的免疫反应较差。
Vaccine. 2022 Nov 15;40(48):6971-6978. doi: 10.1016/j.vaccine.2022.10.042. Epub 2022 Oct 25.
4
COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.失代偿期肝硬化患者的 COVID-19 疫苗：一项回顾性队列研究，评估安全性数据和与未接种状态相关的风险因素。
Infect Dis Poverty. 2022 May 16;11(1):56. doi: 10.1186/s40249-022-00982-0.
5
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.BNT162b2 mRNA 疫苗和 mRNA-1273 疫苗与肝硬化患者 COVID-19 感染和住院的关联。
JAMA Intern Med. 2021 Oct 1;181(10):1306-1314. doi: 10.1001/jamainternmed.2021.4325.
6
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.肝移植受者和慢性肝病患者接种新冠疫苗后的抗体反应分析。
J Hepatol. 2021 Dec;75(6):1434-1439. doi: 10.1016/j.jhep.2021.08.008. Epub 2021 Aug 26.
7
Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.炎症性肠病患者接种 SARS-CoV-2 疫苗后抗体生成受损：一项泛希腊注册研究的结果。
Inflamm Bowel Dis. 2023 Feb 1;29(2):228-237. doi: 10.1093/ibd/izac068.
8
[Liver cirrhosis].[肝硬化]
Z Gesamte Inn Med. 1956 Apr 15;11(8):337-41.
9
[COVID-19 vaccine safety].[新冠病毒疫苗安全性]
Rev Peru Med Exp Salud Publica. 2021 Oct-Dec;38(4):634-642. doi: 10.17843/rpmesp.2021.384.9308. Epub 2022 Apr 1.
10
[From infectious hepatitis to liver cirrhosis].[从传染性肝炎到肝硬化]
Schweiz Z Pathol Bakteriol. 1953;16(3):376-81.

引用本文的文献

1
Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.评估门诊患者中熊去氧胆酸对新型冠状病毒肺炎的保护效果及危险因素。
Front Pharmacol. 2024 Jul 31;15:1381830. doi: 10.3389/fphar.2024.1381830. eCollection 2024.
2
Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis.熊去氧胆酸与肝硬化患者的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染减少及新型冠状病毒肺炎（COVID-19）严重程度降低有关。
J Intern Med. 2023 May;293(5):636-647. doi: 10.1111/joim.13630. Epub 2023 Apr 5.

本文引用的文献

1
Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study.抗体反应和肝硬化患者使用 ChAdOx1-nCOV（Covishield）的安全性：一项横断面、观察性研究。
Dig Dis Sci. 2023 Feb;68(2):676-684. doi: 10.1007/s10620-022-07641-2. Epub 2022 Sep 25.
2
Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis.COVID-19病毒载体Ad.26.COV2.S疫苗在肝硬化患者中的有效性及与mRNA疫苗的比较
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2405-2408.e3. doi: 10.1016/j.cgh.2022.05.038. Epub 2022 Jun 16.
3
Comparison of infection-induced and vaccine-induced immunity against COVID-19 in patients with cirrhosis.比较肝硬化患者感染诱导和疫苗诱导的 COVID-19 免疫反应。
Hepatology. 2023 Jan 1;77(1):186-196. doi: 10.1002/hep.32619. Epub 2022 Jul 5.
4
Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis.接种疫苗后 COVID-19 感染与肝硬化患者死亡率降低有关。
Hepatology. 2022 Jul;76(1):126-138. doi: 10.1002/hep.32337. Epub 2022 Feb 22.
5
SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients.肝硬化和肝移植患者第二次接种后针对 SARS-CoV2 的体液和 T 细胞免疫应答。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9. doi: 10.1016/j.cgh.2021.09.003. Epub 2021 Sep 9.
6
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.肝移植受者和慢性肝病患者接种新冠疫苗后的抗体反应分析。
J Hepatol. 2021 Dec;75(6):1434-1439. doi: 10.1016/j.jhep.2021.08.008. Epub 2021 Aug 26.
7
Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study.慢性肝病和肝硬化患者感染 SARS-CoV-2 的结果：一项全国 COVID 队列协作研究。
Gastroenterology. 2021 Nov;161(5):1487-1501.e5. doi: 10.1053/j.gastro.2021.07.010. Epub 2021 Jul 18.
8
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.BNT162b2 mRNA 疫苗和 mRNA-1273 疫苗与肝硬化患者 COVID-19 感染和住院的关联。
JAMA Intern Med. 2021 Oct 1;181(10):1306-1314. doi: 10.1001/jamainternmed.2021.4325.